Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

24 mai 2005 09h40 HE | Source: ViroPharma Incorporated

ViroPharma Announces Advancement of HCV-796 Into Phase 1B Clinical Testing In Hepatitis C Patients

EXTON, Pa., May 24, 2005 (PRIMEZONE) -- ViroPharma Incorporated (Nasdaq:VPHM) today announced the commencement of a Phase 1b proof of concept clinical study in hepatitis C positive patients with...
29 avr. 2005 02h09 HE | Source: Crucell N.V.

Crucell N.V.: Single-Shot Outbreak Vaccine Provides Full Protection Against Ebola According to Results of New Animal Studies

LEIDEN, Netherlands, April 29, 2005 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) today reported new results from its Ebola vaccine studies. The studies,...
15 avr. 2005 10h30 HE | Source: Care Choices

Care Choices and St. Mary Mercy Hospital Support Day of Family Fun, Fitness

FARMINGTON HILLS, Mich., April 15, 2005 (PRIMEZONE) -- In an effort to encourage families to make fitness a priority, Care Choices HMO is teaming up with the Livonia Community Recreation Center and...
08 avr. 2005 08h30 HE | Source: Universal Detection Technology

Universal Detection Technology Comments on U.S. House of Representatives Oversight Hearing on Anthrax Detection Methods

LOS ANGELES, April 8, 2005 (PRIMEZONE) -- Universal Detection Technology (OTCBB:UDTT) today commented on a hearing held on April 5, 2005 by The Committee on Government Reform's Subcommittee on...
10 mars 2005 16h01 HE | Source: ViroPharma Incorporated

ViroPharma Announces Data From HCV-086 Proof of Concept Study

EXTON, Pa. , March 10, 2005 (PRIMEZONE) -- ViroPharma Incorporated (Nasdaq:VPHM) today announced results from the Phase 1b proof of concept study with HCV-086, an orally dosed hepatitis C (HCV)...
14 févr. 2005 11h15 HE | Source: ViroPharma Incorporated

ViroPharma Announces Start of HCV-796 Phase 1 Program

EXTON, Pa., Feb. 14, 2005 (PRIMEZONE) -- ViroPharma Incorporated (Nasdaq:VPHM) today announced that dosing has begun in the Phase 1 clinical trial for HCV-796, a novel polymerase inhibitor being...
27 janv. 2005 12h35 HE | Source: E Team, Inc.

E Team Ensures Law Enforcement and Public Health Communications, Collaboration, and Response at Bush Inauguration

LOS ANGELES, Jan. 27, 2005 (PRIMEZONE) -- E Team, Inc., the proven, market-leading provider of collaborative software for crisis management, announced that five separate E Team crisis management...
17 janv. 2005 11h00 HE | Source: Bitfone Corporation

Bitfone Expands Asia Operations and Relocates China Development Center to Beijing

LAGUNA NIGUEL, Calif., Jan. 17, 2005 (PRIMEZONE) -- Bitfone Corporation (www.bitfone.com), the company that pioneered firmware over-the-air (FOTA) update technology for mobile phones, today announced...
06 janv. 2005 11h10 HE | Source: ViroPharma Incorporated

ViroPharma Announces Submission of Investigational New Drug Application for HCV-796

EXTON, Pa., Jan. 6, 2005 (PRIMEZONE) -- ViroPharma Incorporated (Nasdaq:VPHM) today announced that its partner in the development of antiviral compounds targeting hepatitis C (HCV), Wyeth...
14 déc. 2004 06h00 HE | Source: Pure H2O Bio-Technologies, Inc.

Pure H20 Bio-Technologies, Inc. Announces New Filing of U.S. Patent Application for Iodine Water Treatment System and Method

BOCA RATON, Fla., Dec. 14, 2004 (PRIMEZONE) -- Pure H20 Bio-Technologies, Inc. (Pink Sheets:PHBT) announced today it filed a new Patent Application with the United States Patent and Trademark Office,...

Page précédente